First Sponsor (ADN) Q1 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2024 TU earnings summary
29 Oct, 2026Executive summary
PRC property buying sentiment remained subdued in 1Q2024; staged handovers across most development projects are planned during FY2024, with stronger buyer confidence potentially adding sales recognition.
European portfolio operating income rose 31.1% YoY to €7.9m, while hotel performance diverged: European hotels improved and Chengdu Wenjiang hotels weakened.
Financial highlights
European property operating income was €7.874m in 1Q2024, up 31.1% YoY from €6.006m; Dutch office income rose 10.6% to €5.868m and hotel income increased 187.4% to €2.006m.
European hotels recorded revenue of €24.18m, up 5.8% YoY, and EBITDA of €0.91m versus LBITDA of €0.36m in 1Q2023.
Chengdu Wenjiang hotels' revenue fell 6.8% YoY to RMB18.10m and EBITDA declined 61.6% to RMB1.55m.
Outlook and guidance
Most PRC development projects are expected to hand over units in stages during FY2024; potential improvement in buying confidence could support additional sales recognition within the year.
Time Zone Phase 1.2's final two residential blocks and remaining SOHO block are now expected to launch for pre-sales in 2H2024, delayed from 1H2024 due to subdued demand.
Meerparc aims to sign a municipal agreement in 2Q2024 and apply for its building permit in 2H2024; Dreeftoren office and residential towers target completion in 2Q2025 and 2Q2026.
Puccini Milan hotel and Le Méridien Frankfurt renovation are expected to start in 2H2024 and complete in 1H2025; PRC property-financing loans are expected to decline further during FY2024.
Latest events from First Sponsor
- European income grew as PRC presales stayed weak; NSI profit and S$244m rights proceeds bolstered 3Q.ADN
Q3 2024 TU - FY2023 profit fell 90.5% as European property income and equity proceeds supported resilience.ADN
H2 2023 - Revenue rose 27.2% and profit 12.4%, despite weak PRC pre-sales and higher financing costs.ADN
H1 2024 - NSI earnings lifted FY2024 profit despite PRC weakness and impairment charges.ADN
H2 2024 - Weak PRC presales contrast with stable European income and progress on loan recovery.ADN
Q1 2025 - Attributable profit rose 59.2% despite lower revenue and subdued PRC pre-sales.ADN
H1 2025 - Loan recovery and refinancing bolster flexibility as PRC sales stay weak and European income edges higher.ADN
Q3 2025 TU - Derivative losses drove FY2025 reported loss despite adjusted profit and stronger European hotels.ADN
H2 2025 - H1 attributable loss reached S$92.8m as derivatives and Humen impairment offset European NOI growth.ADN
H1 2026